Compare BANF & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BANF | TWST |
|---|---|---|
| Founded | 1984 | 2013 |
| Country | United States | United States |
| Employees | 2260 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.0B |
| IPO Year | N/A | 2018 |
| Metric | BANF | TWST |
|---|---|---|
| Price | $115.91 | $76.38 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $124.00 | $46.88 |
| AVG Volume (30 Days) | 125.5K | ★ 1.6M |
| Earning Date | 04-16-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $376,572,000.00 |
| Revenue This Year | $6.10 | $18.91 |
| Revenue Next Year | $3.92 | $15.07 |
| P/E Ratio | $16.38 | ★ N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $101.48 | $23.30 |
| 52 Week High | $138.15 | $80.50 |
| Indicator | BANF | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 63.45 | 68.55 |
| Support Level | $106.29 | $41.85 |
| Resistance Level | $122.05 | $80.50 |
| Average True Range (ATR) | 2.50 | 4.77 |
| MACD | 0.70 | 0.60 |
| Stochastic Oscillator | 92.49 | 77.94 |
BancFirst Corp is engaged in providing banking services. The company's business unit includes BancFirst metropolitan banks, BancFirst community banks, Pegasus Bank, Worthington, other financial services and executive, operations and support. BancFirst metropolitan banks, BancFirst community banks, Pegasus and Worthington offer traditional banking products such as commercial and retail lending and a full line of deposit accounts. Its Other financial services are specialty product business units including guaranteed small business lending, residential mortgage lending, trust services, securities brokerage, electronic banking, and insurance.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.